Abstract 922P
Background
Genomic instability is an hallmark of cancer that has been associated to immune evasion, cancer progression and multidrug resistance. MOSCATO (NCT) was a prospective clinical trial evaluating the clinical benefit of high-throughput genomic analyses in patients with advanced solid tumors. In this study we investigated a genomic instability score based on somatic copy number alterations as determined by Single Nucleotide Polymorphism (SNP) array as a biomarker for head and neck cancer patients.
Methods
Extracted DNA from fresh frozen tumor was analyzed using high-resolution Affymetrix Cytoscan® HD array whereas extracted DNA from FFPE samples was analyzed using the Affymetrix Oncoscan® CNV assay. The absolute copy-number (ACN) profile was generated by ASCAT v3.1 through EaCoN v0.3.6 (https://github.com/gustaveroussy/EaCoN, PMID 36669143) on R v4.1.1 and then the genomic instability score (GIS) was estimated as the sum of the segment length multiplied by the absolute difference between segment copy number and the ASCAT estimated sample ploidy. This sum is reported to the reference genome length. In parallel, somatic mutation were assessed with a NGS panel covering including at least 75 critical oncogenes and tumor suppressor genes.
Results
SNP array data were available for 58 patients out of the 111 with head and neck cancers. 38 were men, 34 had squamous histology (SCC), 13 cystadenocarcinoma (ACC) and 11 other types (adenocarcinoma, mucinous carcinoma). Patients with SCC had higher GIS (median 0.53 for SCC vs 0.05 for ACC and 0.40 for others). At genomic level, the presence of TP53 (p < 0.001) and ATM (p 0.056) were associated with higher GIS. This was confirmed also after adjusting for histology. Conversely, GIS score was not associated with age. Patients with SCC that were positive for HPV (n=11) had lower GIS respect to HPV negatives (n=14, 0.24 vs 0.85, p 0.05) Higher GIS score was associated with decreased OS after adjusting for histology (HR 1.87, 95% CI 1.31 - 2.65, p < 0.001).
Conclusions
Genomic instability score based on SNP array copy number alterations profile is associated with worse prognosis in patients with carcinoma of the head and neck. Higher GIS score is found in squamous cell carcinomas and is associated with mutations in genes involved in cell cycle control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors
Presenter: Qizhi Ma
Session: Poster session 03
1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
Presenter: Toshihiko Doi
Session: Poster session 03
1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Presenter: Samuel Klempner
Session: Poster session 03
1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer
Presenter: Omar Saavedra Santa Gadea
Session: Poster session 03
1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion
Presenter: Bo Cheng
Session: Poster session 03
Resources:
Abstract
1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01
Presenter: Athanasia Dasargyri
Session: Poster session 03
1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC
Presenter: Adel Benlahrech
Session: Poster session 03
1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Jonathan Riess
Session: Poster session 03
1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer
Presenter: Douglas McNeel
Session: Poster session 03
1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03